UroGen Pharma Ltd. logo URGN - UroGen Pharma Ltd.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 4
SELL 0
STRONG
SELL 0
| PRICE TARGET: $42.50 DETAILS
HIGH: $45.00
LOW: $40.00
MEDIAN: $42.50
CONSENSUS: $42.50
UPSIDE: 47.11%

Stock News

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue.

May 07, 2026 11:59 AM • seekingalpha.com
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7% Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026 UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17 th at 8:30 AM ET Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

May 06, 2026 04:00 AM • globenewswire.com
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers

UroGen Pharma faces a pivotal period as ZUSDURI, its recently approved bladder cancer therapy, is positioned for accelerated adoption following a permanent J-Code in 2026. ZUSDURI's peak sales are anticipated at $1 billion by 2030, with a four-year ramp, but near-term revenue guidance will not be provided until at least Q2–Q3 2026. URGN's liquidity improved to $245.5 million after a revised Pharmakon loan, yet cash burn remains high and ZUSDURI's commercial success is critical for financial stability.

Mar 04, 2026 08:53 PM • seekingalpha.com
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J Code Permanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient access JELMYTO ® achieved net product sales of $94 million in 2025, representing year-over-year underlying demand sales growth of 7% Announced refinancing of existing term loan with Pharmakon Advisors that provides additional non-dilutive capital at more favorable terms Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

Mar 02, 2026 03:00 AM • globenewswire.com

Price Targets